Merck KGaA has completed the acquisition of the chromatography business of JSR Life Sciences, strengthening its capabilities in biopharmaceutical manufacturing.

The deal adds advanced Protein A chromatography technologies, including Amsphere™ resins, to Merck’s downstream processing portfolio, enabling more efficient and scalable purification of monoclonal antibodies. This is expected to enhance productivity and support reliable manufacturing from development through commercial scale.

The acquisition also brings a Belgium-based team of more than 50 employees with expertise in chromatography solutions, further reinforcing Merck’s technical capabilities and customer support offering.

Merck stated that the expanded portfolio will help biopharma companies accelerate production processes and improve access to critical therapies, aligning with growing demand for scalable biologics manufacturing solutions.